The program will use Corindus’ CorPath robotic-assistance system designed for coronary PCI procedures. The system allows operating physicians to avoid radiation exposure and orthopedic strain from wearing lead protective vestments by operating from a remote location, the Waltham, Mass.-based company said.
“The occupational hazards in this field can be devastating to people. Vascular robotics provide the biggest change to cath lab procedures in 30 years and is transforming the environment by reducing radiation exposure and spinal stresses to physicians and providing robotic precision of interventional device manipulation. Collaboration between Corindus and leading physicians and scientists is an important and exciting step toward accelerating the progress currently being made by robotic technology in the cardiology field,” CEO David Handler said in a prepared statement.
Research at the Mayo Clinic is being led by cardiologist Dr. Gurpreet Sandhu and cardiac catheterization lab director Dr. Earl Wood.
The project comes following an article published in April in the Journal of the American College of Cardiology that highlighted interventional laboratory health hazards based on Mayo Clinic research, Corindus said.
Last week, Corindus said it won FDA 510(k) clearance for its robotic-assisted CorPath System for use during percutaneous coronary interventions stenting procedures performed via radial access.
The approval was based on results from a 30-patient clinical trial of the device that demonstrated a 100% device and clinical success rate, the Waltham, Mass.-based company said.